Overview

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib